Astellas VP-Business Development Masaki Doi: An Interview With “The Pink Sheet” DAILY (Part 2 0f 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Exec talks about emerging markets in Asia, and how Astellas’ culture differs from other Japanese pharmas.
You may also be interested in...
Amgen's Phosphate Binder Loss May Be Genzyme's Gain
Amgen is shelving its own development of the phosphate binder AMG 223 for treatment of hyperphosphatemia in chronic kidney disease, after Phase II results disappointed
Amgen's Phosphate Binder Loss May Be Genzyme's Gain
Amgen is shelving its own development of the phosphate binder AMG 223 for treatment of hyperphosphatemia in chronic kidney disease, after Phase II results disappointed
Amgen’s Phosphate Binder Loss May Be Genzyme’s Gain
Once expected to plunder Renagel market share, AMG 223 suddenly gets left on the shelf.